Metabolic characteristics of castleman disease on 18f-FDG PET in relation to clinical implication

Clinical Nuclear Medicine

Volumn 38, Issue 5, 2013, Pages 339-342

  Lee, Eun Seong ^a   Paeng, Jin Chul ^b   Park, Chang Min ^b,c   Chang, Won ^c   Lee, Won Woo ^a   Kang, Keon Wook ^a,b   Chung, June Key ^a,b   Lee, Dong Soo ^a  

^a Department of Biochemistry and Molecular Biology   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

18F FDG PET CT; Castleman disease; multicentric; SUVmax; unicentric

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG UPTAKE; FEMALE; HUMAN; HYPERMETABOLISM; IMAGE ANALYSIS; LYMPH NODE; MALE; PROGNOSIS;

AGED; BIOLOGICAL TRANSPORT; FEMALE; FLUORODEOXYGLUCOSE F18; GIANT LYMPH NODE HYPERPLASIA; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84876414513     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182816730     Document Type: Article

References (13)

1. Cabot RC, Castleman B, Towne VW. Case 40011. N Engl J Med. 1954;250: 26-30.
2. Shin D, Jeon YK, Hong Y, et al. Clinical dissection of multicentric Castleman disease. Leuk Lymphoma. 2011;52:1517-1522.
3. Enomoto K, Nakamichi I, Hamada K, et al. Unicentric and multicentric Castleman's disease. Br J Radiol. 2007;80:e24-e26.
4. Madan R, Chen JH, Trotman-Dickenson B, et al. The spectrum of Castleman's disease: mimics, radiologic pathologic correlation and role of imaging in patient management. Eur J Radiol. 2012;81:123-131.
5. Murphy SP, Nathan MA, Karwal MW. FDG-PET appearance of pelvic Castleman's disease. J Nucl Med. 1997;38:1211-1212. (Pubitemid 27332615)
6. Barker R, Kazmi F, Stebbing J, et al. FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease. Eur J Nucl Med Mol Imaging. 2009;36:648-652.
7. Polizzotto MN, Millo C, Uldrick TS, et al. [18F]-fluoro-d-deoxyglucose positron emission tomography findings in Kaposi sarcoma herpes virus associated multicentric Castleman disease: correlation with clinical, inflammatory, and virologic parameters [abstract]. Infect Agent Cancer. 2012;7:1-2.
8. El-Osta HE, Kurzrock R. Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist. 2011;16:497-511.
9. van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel antiYinterleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol. 2010;28:3701-3708.
10. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the IL-6 receptor. Annu Rev Pharmacol Toxicol. 2012;52:199-219.
11. Yuzuriha A, Saitoh T, Koiso H, et al. Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by antiY interleukin-6 receptor antibody (tocilizumab) therapy. Acta Haematol. 2011; 126:147-150.
12. Blockmans D, Maes A, Stroobants S, et al. FDG positron emission tomographic scintigraphy can reveal Castleman's disease as a cause of inflammation. Clin Nucl Med. 2001;26:975-976. (Pubitemid 33020361)
13. Bertagna F, Biasiotto G, Rodella R, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography findings in a patient with human immunodeficiency virus-associated Castleman's disease and Kaposi sarcoma, disorders associated with human herpes virus 8 infection. Jpn J Radiol. 2010; 28:231-234.